My watch list  

CureVac, Sanofi Pasteur and In-Cell-Art Collaborate on a $33.1 Million Project Co-Funded by the U.S. Defense Advanced Research Projects Agency

4-year collaboration in field of prophylactic and therapeutic vaccines for infectious diseases


CureVac GmbH announced the signing of several agreements with Sanofi Pasteur S.A., the vaccines division of Sanofi. Under these agreements, CureVac and Sanofi Pasteur will further develop and apply CureVac’s proprietary RNActive® technology platform to the development of vaccines against several infectious diseases.

A research proposal with total funding of $33.1 million involving a collaboration among CureVac, Sanofi Pasteur (including Sanofi Pasteur VaxDesign Corp.) and In-Cell-Art S.A.S., a French biotech company contributing its nanoparticle technology, has been selected by DARPA, the Defense Advanced Research Projects Agency (an agency of the United States Department of Defense). In this 4-year project, CureVac and the other parties to the collaboration will further advance key aspects of CureVac’s RNActive® technology platform and will evaluate several vaccine candidates in a number of relevant disease models

Parallel to the collaboration agreements, CureVac and Sanofi Pasteur have also signed an option agreement with pre-agreed license terms for several pre-defined pathogens. Sanofi Pasteur’s option rights are linked to fulfillment of certain agreed acceptance criteria relating to the DARPA project. CureVac retains the rights to its own core development programs and to all of its background technology for any other pathogens outside those within the Sanofi Pasteur option.

“We are very pleased that Sanofi Pasteur has recognized the full potential of our RNActive® technology platform for the development of vaccines particularly for infectious diseases. This multi-year collaboration will allow us to significantly strengthen our technology platform and to scale it up for commercial vaccination purposes,” says Ingmar Hoerr, CEO of CureVac. “The opportunity to collaborate with a world-leading vaccine company such as Sanofi Pasteur is an exciting step as we continue to demonstrate in both the commercial and defense-related settings the broad applicability and versatility of our RNActive® technology platform, which may become game changing for the vaccine field,” adds Karl-Josef Kallen, Head of R&D at CureVac.

Under the terms of the license agreements, CureVac may receive an upfront payment from Sanofi Pasteur for each pathogen, research funding and payments for achieving several clinical, regulatory and commercial milestones. For each pathogen subject to Sanofi Pasteur’s option, the agreements could encompass up to €101.5 million for CureVac in upfront and milestone payments in addition to tiered royalties on sales of RNActive® vaccines if Sanofi Pasteur develops a prophylactic or a therapeutic vaccine against such pathogen and up to €150.5 million if Sanofi-Pasteur develops both a prophylactic and a therapeutic vaccine. Under the license agreements, Sanofi Pasteur will fund all research and development activities and will have exclusive marketing rights worldwide for RNActive® vaccines against the pathogens for which Sanofi Pasteur has exercised the option.

Facts, background information, dossiers
  • Sanofi Pasteur
  • CureVac
  • In Cell Art
More about CureVac
  • News

    CureVac Establishes U.S. Operations in Cambridge, MA

    CureVac announced the official launch of its U.S. operations in Cambridge, MA, as the company advances the development of its proprietary mRNA platform technologyand multiple, clinical-stage mRNA therapeutics and vaccines. The expansion into the U.S. extends the company’s footprint into one ... more

    Boehringer Ingelheim and CureVac announce collaboration to develop next generation lung cancer immunotherapy

    Boehringer Ingelheim and CureVac, leader in mRNA (messenger ribonucleic acid)-based drug development, today jointly announce an exclusive global license and development collaboration. The new collaboration focuses on CureVac’s CV9202, a novel investigational therapeutic mRNA vaccine in earl ... more

    CureVac Presents Results of a Phase I/IIa Trial in Non-Small Cell Lung Cancer (NSCLC) with CV9201

    CureVac GmbH presented the results of a Phase I/IIa trial in non-small cell lung cancer (NSCLC) with CV9201, an mRNA-based cancer vaccine, in patients with NSCLC stage IIIB/IV after first-line chemo-radiotherapy or chemotherapy, respectively. The trial strived to assess safety and toxicity ... more

  • Events
    01-11 – 02-11
    Berlin, DE

    5th International mRNA Health Conference

    The 5th International mRNA Health Conference is the premier meeting destination for professionals and academia in the field of mRNA drugs. In its fifth year, the conference is returning to Berlin to celebrate the remarkable research, preclinical and clinical progress of the past year. The e ... more

  • Job Offers

    Senior Manager Regulatory Affairs CMC (f/m)

    To boost our team in Frankfurt or Tübingen near Stuttgart, we are currently looking to recruit a Life Scientist / Biotechnologist / Pharmacist as Senior Manager Regulatory Affairs CMC (f/m) The Manager Regulatory Affairs CMC develops the global regulatory strategy for the CMC area from the ... more

More about Sanofi Pasteur
More about In Cell Art
More about U.S. Defense Advanced Research Projects Agency
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE